Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Special Report Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech SectorAuthor: Jeffrey Neal Johnson. Article Posted: 2/24/2026. 
Summary - Johnson & Johnson has maintained an impressive streak of increasing its dividend payouts for generations, rewarding long-term shareholders with reliable income.
- Management is driving future expansion by focusing on high-growth pharmaceutical assets and cutting-edge medical technologies, such as robotics.
- Investors looking for shelter from market volatility benefit from a stock that historically moves much less than the broader market indices.
While the technology sector faces renewed volatility driven by artificial intelligence (AI) scare trades and valuation concerns, a different story is unfolding in the healthcare sector. Investors fleeing the jittery price swings of high-growth tech stocks are finding shelter in a familiar name that is quietly outperforming. Johnson & Johnson (NYSE: JNJ) is trading near all-time highs of roughly $245 per share, creating a divergence that has caught Wall Street's attention. This rally undercuts the common perception of the healthcare giant as a slow-moving, boring stock. In the past 30 days, shares have climbed about 14%, significantly outpacing the broader market during a period of uncertainty. That price action suggests institutional money is rotating out of riskier assets and placing a premium on stability, predictable cash flow, and solid execution. For investors watching the ticker on Feb. 24, 2026, note a specific calendar event: today is the ex-dividend date for Johnson & Johnson. The stock price will typically drop by the amount of the upcoming dividend, $1.30 per share, which is a mechanical market adjustment rather than a reflection of operating performance. For income-focused investors, that technical dip often represents an attractive entry point. 64 Years of Unbroken Growth The main reason many investors hold Johnson & Johnson through turbulent cycles is its financial stability and role as a portfolio stabilizer. The company is part of an elite group known as Dividend Kings, firms that have increased their dividend for at least 50 consecutive years. Johnson & Johnson has now raised its dividend for 64 consecutive years, a record that spans recessions, market crashes, and geopolitical shocks. That consistency is rare in a market focused on speculative growth. The stock yields roughly 2.12%, based on an annual payout of $5.20 per share. While higher yields exist in bonds or riskier sectors, J&J's appeal lies in the mix of growth and safety. Management projects free cash flow of about $21 billion in 2026, a large liquidity cushion that supports dividend payments, R&D investment, and legal expenses without heavy borrowing. For risk-averse investors, one of the most compelling metrics is the stock's Beta. Beta measures how much a stock moves compared with the overall market (S&P 500). A Beta of 1.0 moves in lockstep with the market; Johnson & Johnson's Beta of 0.35 means it has historically been about 65% less volatile than the broader market. When tech stocks swing wildly, JNJ tends to hold its ground. Adding JNJ to a tech-heavy portfolio acts as a mathematical shock absorber, reducing overall volatility while maintaining equity exposure. Beyond the Patent Cliff: The Road to $100 Billion A common misconception about safe stocks is that they cannot grow. Johnson & Johnson is disproving that with a strategic pivot that appears to be paying off. Management issued strong guidance for 2026, projecting full-year revenue to top $100 billion for the first time in company history and adjusted earnings per share of about $11.53. This growth stems from the reinvention of its pharmaceutical division, now branded as Innovative Medicine. Investors once worried about the patent cliff after Stelara lost exclusivity in 2025. Typically, when a blockbuster drug faces generic competition, revenue collapses. J&J has offset that decline with the rapid ascent of new blockbusters. Two key assets driving this resilience: - Darzalex: An oncology workhorse generating about $14 billion in annual sales, Darzalex has become a cornerstone therapy in treating multiple myeloma.
- Tremfya: Poised as a successor in immunology, Tremfya released strong three-year remission data for ulcerative colitis, helping J&J preserve market share in a competitive space.
The Tech in MedTech: High-Margin Technologies The growth story extends beyond pharmaceuticals into MedTech. This segment has shifted to focus on high-growth, higher-margin technologies, exemplified by the integration of Shockwave Medical to modernize the cardiovascular portfolio. Shockwave uses intravascular lithotripsy (IVL) technology, which applies sonic pressure waves to break up calcified plaque in arteries—conceptually similar to treatments for kidney stones. That is a meaningful improvement over traditional angioplasty balloons. Owning this technology gives Johnson & Johnson a high-growth asset that complements its existing cardiovascular and surgical businesses. J&J is also advancing in robotics. The submission of its Ottava robotic surgical system for FDA approval signals an intent to compete in the expanding soft-tissue robotics market. These high-tech devices carry higher profit margins and create sticky relationships with hospital systems, offering a long-term earnings tailwind beyond basic surgical tools. Addition by Subtraction: The Orthopedics Strategy To sustain growth and improve margins, management is reshaping the corporate structure. A major development is the potential separation or sale of the DePuy Synthes orthopedics business. While a spin-off was originally planned, recent reports suggest the company is exploring a large sale of the unit. Divesting the orthopedics business is an example of addition by subtraction. Orthopedics is a mature, lower-growth segment compared with booming fields like oncology and advanced cardiovascular devices. Selling the unit would likely improve the company's top-line growth rate and margins, and generate significant cash proceeds that could fund acquisitions, debt reduction, or share buybacks. No discussion of J&J is complete without addressing legal risks. The company continues to face litigation over talc products, with a recent $1.5 billion verdict keeping the issue in the headlines. A separate commercial lawsuit from Bayer over marketing claims for prostate cancer drugs has also added noise to the news cycle. Still, the stock's recent rally suggests investors are looking past these headlines. Bulls argue J&J has the financial depth to manage liabilities without disrupting operations. With more than $20 billion in cash and marketable securities, potential proceeds from any orthopedics sale, and roughly $21 billion in projected free cash flow, the company has the resources to absorb settlements. For now, legal battles look more like balance-sheet items than existential threats to the dividend or business model. Capital Preservation With Upside Johnson & Johnson has evolved from a diversified conglomerate into a more focused, higher-tech healthcare company. After spinning off its consumer health division (Kenvue (NYSE: KVUE)) and potentially divesting orthopedics, management is concentrating on pharmaceuticals and medical technology. Although the stock trades near record highs and is no longer a deep-value play, it offers a rare mix of capital preservation and upside. The combination of a 64-year dividend growth streak, a low volatility profile, and a clear path to $100 billion in revenue makes J&J a compelling option for 2026. For investors tired of the tech sector's unpredictability, Johnson & Johnson is a reminder that, in the current market, boring can be both beautiful and profitable.
| 
